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Chagas disease, which is caused by Trypanosoma cruzi (T. cruzi), remains a substantial public health concern and an important
cause of morbidity and mortality in Latin America. T. cruzi infection causes an intense inﬂammatory response in diverse tissues by
triggeringlocal expression ofinﬂammatorymediators,which resultsintheupregulation ofthelevels ofcytokines andchemokines,
and important cardiac alterations in the host, being one of the most characteristic damages of Chagas disease. Therefore,
controlling the inﬂammatory reaction becomes critical for the control of the proliferation of the parasite and of the evolution
of Chagas disease. The nuclear receptors known as peroxisome proliferator-activated receptors (PPARs) have emerged as key
regulators of lipid metabolism and inﬂammation. The precise role of PPAR ligands in T. cruzi infection or in Chagas disease is
poorly understood. This review summarizes our knowledge about T. cruzi infection as well as about the activation of PPARs and
the potential role of their ligands in the resolution of inﬂammation, with the aim to address a new pharmacological approach to
improve the host health.
1.Introduction
Chagas disease is widely distributed throughout Latin Amer-
ica,thuscausingaseriouspublichealthproblem.Itisconsid-
ered the parasitic disease that leads to the greatest economic
burden in Latin America due to its prolonged chronicity.
Reasonably, public control programs normally focus their
resources and strategies on the elimination of insect vectors
associated with human habitat and relegate the infected
patient. Moreover, migration from rural to urban areas has
changed the epidemiology of the disease. While in the 1930’s
70% of Latin Americans lived in rural areas, currently about
70% live in urban areas. The infection was primarily rural
and became urban transmissible by blood transfusion. In
recent decades, the number of donors with positive serology
has increased in endemic countries. Thus, there is a need for
new strategies to prevent or stop the cardiac consequences
of T. cruzi infection, with an aﬀordable cost to the health
system and patients. The host responds to invasion by the
activation of inﬂammation and induction of innate and
speciﬁc immunity. The infectious inﬂammatory myocarditis
generated by T. cruzi induces an inﬂammatory response that
aﬀects the heart tissue and function. Moreover, the immune
system can act with autoimmune reaction with inﬁltration
of macrophages and/or cell-damaging attack. Therefore,
the anti-inﬂammatory actions of peroxisome proliferator-
activated receptors (PPARs) γ and α have received great
attention because of the availability of synthetic PPAR
activators. PPAR ligands emerge as attractive drug targets for
lipid and glucose metabolism as well as for inﬂammation
resolution. The aim of this article is to review the role of
PPARs in T. cruzi infection and their potential contribution
to inﬂammation resolution.
2.ChagasDisease
Chagas disease, also called American trypanosomiasis, is a
chronic and systemic parasitic infection caused by the pro-
tozoan Trypanosoma cruzi. This parasite was discovered2 PPAR Research
in 1909 by the Brazilian physician Carlos Chagas (1879–
1934), who described in detail the cycle of transmission and
the human clinical manifestations.
This infectious disease is endemic throughout Central
and South America and is still recognized by the World
Health Organization (WHO) as one of the most important
ignored tropical diseases and as a signiﬁcant public health
problem. In recent decades, the increased rate of emigra-
tion from Chagas-endemic countries to the United States,
Canada, and the European Union has become a new concern
for the WHO [1].
T. cruzi has several instances of transmission to humans
and other susceptible hosts, mainly through contact with the
fecesofinfectedblood-feedinginsectvectors.However,alter-
native routes such as blood transfusion, organ transplant,
congenitaltransmissionandoraltransmissionhavealsobeen
determined [2].
The clinical course of the infection has two phases: an
acute and a chronic. The acute phase is characterized by
evident parasitemia and parasitism in a wide variety of
host cells. This phase can be confused with other infections
since symptoms such as fever or hepatomegaly and/or
splenomegaly are shared by diﬀerent infectious diseases.
Most of the patients that survive the acute phase remain in
a life-long asymptomatic state (indeterminate form) during
the chronic phase of infection [3].
During the acute phase of infection, most individuals
usuallyhavemildsymptomssuchasfever,whichdonotneed
medical attention, with few or no parasites found in circula-
tion. Symptoms of acute infection may last up to a few weeks
or months. Although the infection then remains largely asy-
mptomatic, often for years or even decades, 30% of patients
develop chronic Chagas disease [4].
Symptoms of the acute phase resolve spontaneously in
about 90% of infected patients even if the infection is not
treated with trypanocidal drugs. About 60–70% of these
patients will never develop clinically apparent disease. These
patients have the indeterminate form of chronic Chagas dis-
ease. The remaining 30–40% of patients will develop a form
of chronic disease characterized by progression to cardi-
ac disease, gastrointestinal disease, or both, over a period of
years to decades [3, 5, 6].
The cardiomyopathy in South and Central America de-
velops manifestations like cardiac arrhythmias, apical aneu-
rysms, congestive heart failure, thromboembolism, and sud-
den cardiac death in disease-endemic areas [7]. As expected,
Chagas disease can be reactivated in patients with HIV/AIDS
or subject to chemotherapy [8].
It has been described that Chagas disease is typiﬁed by
a chronic inﬂammatory process that causes damage to the
myocardium as well as to the conduction system. The patho-
genesismayinvolveseveralmechanisms,includingimmuno-
logically mediated tissue damage, cardiac dysfunction, and
coronary microvascular disease [9]. There are substantial
evidences showing that cardiac tissue, an important target
of T. cruzi, produces marked amounts of proinﬂammatory
cytokines, chemokines, and enzymes including inducible
nitric oxide (NO) synthase (NOS2) and metalloproteinases
(MMPs), resulting in inﬂammation and cardiac remodeling
in response to parasite infection [10–12].
3. The Peroxisome Proliferator-Activated
Receptors (PPARs) Family
PPARs are members of the nuclear receptor superfamily of
ligand-activated transcription factors. The PPAR subfamily
(NR1C) includes PPAR-α (NR1C1), PPAR-β (also called
PPAR-δ) and NUC1, NR1C2, and PPAR-γ (NR1C3) [13],
each with diﬀerent ligands, target genes, and biological role.
MostofthesePPARsshareasimilarstructure,whichincludes
an amino-terminal activation domain (AF-1), a DNA-bind-
ingdomain,aligand-bindingdomain,andasecondcarboxy-
terminal activation domain (AF-2) [14]. In response to
ligand binding, these receptors change their conformational
structure recruiting coactivators and freeing corepressors.
The PPAR family not only regulates metabolic processes
but also participates in extrametabolic processes, including
direct activation of genes, ligand-independent repression,
ligand-dependent repression, and transrepression [15].
Nuclear receptors can be activated by ligand-dependent
or -independent mechanisms. PPARs are activated by xeno-
bioticsaswellasbyendogenousfattyacidsandtheirmetabo-
lites. PPARs activate the transcription of their target genes
as heterodimers with retinoid X receptors (RXRs), which
are activated by 9-cis retinoic acid [16, 17]. Eicosanoids are
some of the endogenous ligands that bind to the PPAR-RXR
complex, leading to conformational changes, freeing the co-
repressor, and thus binding to the response element of target
genes [15]( Figure 1). PPARs have been cloned in several
species,includingrodents,amphibians,teleosts,cyclostomes,
and even humans. The PPAR subtypes (α, β,a n dγ)a r e
expressed diﬀerently according to the tissue but may also be
coexpressed in diﬀerent relative concentrations [18].
3.1. PPAR-α. PPAR-α was identiﬁed in the early 1990s on
the basis of it being a target of hypolipidemic ﬁbrate drugs
and other compounds that induce peroxisome proliferation
in rodents [19]. PPAR-α is expressed in cells that have active
fatty acid oxidation like hepatocytes, cardiomyocytes, ente-
rocytes, smooth muscle cells, and kidney cells and has been
implicated in the regulation of cellular energetic processes.
It has been shown that PPAR-α ligands, such as ﬁbrates,
decrease triglyceride levels and reduce the incidence of car-
diovascular events and atherosclerosis [20]. The ﬁrst
evidence indicating a potential role for PPARs in the inﬂam-
matory response was the demonstration that leukotriene B4,
a proinﬂammatory eicosanoid, binds to PPAR-α and induces
the transcription of genes involved in ω-a n dβ-oxidation
[21]. It has been described that PPAR-α is expressed in
human and mouse immune cells, including lymphocytes,
macrophages,anddendriticcells,andnumerousstudieshave
implicated PPAR-α in the negative regulation of inﬂamma-
tory responses. Diﬀerent works using PPAR-α ligands have
shown a reduction in the symptoms of inﬂammation and
disease in several models, including models of allergic airway
disease, arthritis, and inﬂammatory intestine disease [22].PPAR Research 3
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Figure 1: A proposed mechanism of ligand-mediated activation
of PPARs. In response to ligand binding, PPARs undergo confor-
mational changes in protein structure. This allows dissociation of
corepressor proteins which inhibit transcription and the recruit-
ment of co-ac-tivators. PPAR-RXR heterodimers bind to speciﬁc
recognition sites of DNA, termed peroxisome proliferator activated
receptorresponseelements(PPREs)locatedintheregulatoryregion
of target genes.
Moreover, the role of PPAR-α in the heart has been shown
with regards not only to the governing of myocardial energy
metabolism and function (using both gain-of-function and
loss-of-function murine models) but also to extrametabolic
activities such as anti-inﬂammatory activities (see [23, 24],
respectively, for a review). There are many works that have
further implicated PPAR-α as an important regulator of
inﬂammatorydisease.Forinstance,ithasbeendemonstrated
that PPAR-α activators inhibit IL-1β-induced IL-6 secretion
by human aortic smooth muscle cells in a dose-dependent
manner [25]. PPAR-α activators also negatively regulate IL-
1β-induced-IL-6 production at the gene expression level by
inhibiting NF-κB transcriptional activity [26]. In addition,
other mechanisms, including alterations in cytokine-rece-
ptor and growth-factor receptor signaling, and the upregu-
lation of the expression of a subunit of the inhibitor of
NF-κB( I κB), have been reported (see [24] for a review).
3.2. PPAR-β/δ. PPAR-β, also known as PPAR-δ, is expressed
ubiquitously and often at higher levels than PPAR-α and
PPAR-γ, suggesting a fundamental role for it in many tis-
sues. PPAR-δ was ﬁrst identiﬁed in Xenopus laevis [27],
and the mouse and human receptors were subsequently
cloned on the basis of sequence similarity with PPAR-α
[17]. PPAR-δ target genes in metabolic tissues are broadly
involvedinfattyacidmetabolism,mitochondrialrespiration,
and thermogenesis. An in vitro study in endothelial cells
has indicated that PPAR-β/δ ligands inhibit TNFα-induced
upregulation of the expression of VCAM-1, MCP-1, and
NF-κB translocation [28] .T h er o l eo fP P A R - δ in the
modulation of inﬂammation is poorly understood. It has
been proposed that, in macrophages, PPAR-β/δ also controls
inﬂammation by its association and disassociation with the
transcriptional repressor BCL-6. It has also been described
that the loss of hematopoietic PPAR-δ expression protects
against atherosclerosis, being the proatherogenic eﬀects of
PPAR-δ due in part to the inﬂuence of PPAR-δ on the
basal expression of inﬂammatory mediators in the arterial
wall. It has also been found that PPAR-δ−/− bone-marrow-
derived macrophages show reduced expression of CCL2,
matrix metalloproteinase 9 (MMP9), and IL-1β and that the
ligand binding to PPAR-δ releases BCL-6, resulting in the
repression of inﬂammatory gene expression [29].
3.3. PPAR-γ. PPAR-γ is the most studied member of the
PPAR family. Two distinct isoforms of PPAR-γ (PPAR-γ1
and PPAR-γ2), which are derived from the same gene but
arise by diﬀerential transcription start sites and alternative
splicing, have been described [30]. This receptor has been
cloned from a number of species, including mice, hamsters,
frogs, pigs, monkeys, and humans [17, 27, 31]. PPAR-γ has
a prominent expression in brown and white adipose tis-
sue, the colon, diﬀerentiated myeloid cells and the placenta
[32]. Brown and white adipocyte tissues are major sites
for PPAR-γ expression. In 1995, Greene et al. identiﬁed
two transcripts corresponding to a full-length mRNA and a
short form devoid of functional domains [31]. More recent
studies have demonstrated that the full-length PPAR-γ is in-
deed expressed in activated T and B cells and mono-
cytes/macrophages [33–35].
ThemainphysiologicalfunctionofPPARsisthemodula-
tion of the expression of speciﬁc target genes [36]. PPAR-γ
is critical for the diﬀerentiation of preadipocytes to adipo-
cytes and also participates in glucose metabolism homeosta-
sis [37, 38]. PPAR-γ can be activated by several physiolo-
gicalligands,suchasdocosahexaenoicacid,linoleicacid,and
some synthetic ones like antidiabetic glitazones, which are
used as insulin sensitizers. Other ligands include oxidized
LDL, azoyle PAF, and eicosanoids, such as 5,8,11,14-eicos-
atetraenoic acid and the prostanoids PGA1,P G A 2,P G D 2,
and the dehydration products of the PGJ series of cyclopen-
tanones, for example, 15-deoxy-Δ12,14-PGJ2 (15dPGJ2)
[39]. In particular, the last one is recognized as an endoge-
nous ligand for the intranuclear receptor PPAR-γ being re-
sponsible for many anti-inﬂammatory functions (see [40]
for a review). However, previous studies have reported
that PPARs inhibit inﬂammatory gene expression by several
mechanisms, including direct interactions with AP1 and NF-
κB[ 41–43], nuclear cytoplasmic redistribution of the p654 PPAR Research
subunitofNF-κB[44],modulationofp38mitogen-activated
proteinkinaseactivity[45],competitionforlimitingpoolsof
coactivators [46], and interactions with transcriptional co-
repressors [29]( s e e[ 47]f o rar e v i e w ) .
PPAR-γ has been reported to regulate inﬂammatory
responses,bothinvivoandinvitro,beinginvolvedinthereg-
ulation of macrophages and endothelial cells, both crucial to
the inﬂammatory response. The presence of PPAR-γ in ma-
crophages was ﬁrst described in studies using human athero-
mas [48–51] .Ar o l ef o rP P A R - γ in T-lymphocyte regulation
has also been described [52]. Furthermore, PPAR-γ is
involved in the diﬀerentiation and activation of monocytes
and in the regulation of their inﬂammatory responses. Pre-
vious works have suggested that diﬀerent stimuli increase
monocytes/macrophages PPAR-γ expression [53, 54]. Anti-
inﬂammatory eﬀects of macrophage PPAR-γ activation have
been demonstrated in a number of studies [55, 56].
The roles of 15dPGJ2 and PPAR-γ in the regulation of
human autoimmune diseases or in animal models of auto-
immunity have been studied by several groups.
15dPGJ2 and other PPAR-γ ligands inhibit inﬂamma-
tion in models of arthritis [57–59], ischemia-reperfusion
injury [60], inﬂammatory bowel disease (IBD) [61–63],
Alzheimer’s disease [64–66], and lupus nephritis [67, 68].
4. Can PPAR Promote or
Preventthe Inﬂammatory Response after
T. cruzi Infection?
Chagas disease is caused by infection with the protozoan
kinetoplastid parasite Trypanosoma cruzi.A c u t eT. cruzi
infection is accompanied by an intense inﬂammatory reac-
tion in many tissues, being usually asymptomatic. When
symptoms occur, they include prolonged fever, enlargement
of the liver, spleen, and lymph nodes, subcutaneous edema
(chagoma) or edema of the ocular mucous membranes
(Roma˜ na’s sign).
There are substantial evidences showing that the cardiac
tissue is an important target of T. cruzi infection. Controlling
the inﬂammatory reaction is critical for the control of the
parasite proliferation in all the tissues, especially in the heart
since it may progress to ﬁbrosis and remodeling, resulting
in a dilated cardiomyopathy accompanied by myocardial
dysfunction [69]. In the context of inﬂammatory response,
in a review of parasitic infections, Chan et al. (2010)
argue that PPAR activation might favor the establishment
of a chronic parasitic infection, making symbiotic survival
between the host and parasite more probable [70]. In this
sense, the adipose tissue has been identiﬁed as one of the
main sites of inﬂammation during Chagas disease progres-
sionwhenculturedadipocytesareinfectedwiththeTulahuen
strain of T. cruzi, demonstrating an increase in the expres-
sion of proinﬂammatory mediators [71]. Fnu Nagajyothi
et al. (2008) described an infection-associated decrease in
adiponectin and PPAR-γ in infected adipocytes. They also
showed that PPAR-γ is highly expressed in adipose tissue
and that, together with the adipokine adiponectin, represses
the inﬂammatory process although the mechanism by which
adiponectin exerts an anti-inﬂammatory eﬀect is unclear
[71]. However, it is clear that a reduction in the level of
adiponectin is associated with an increase in inﬂammation
and that there is an inverse relationship between PPAR-γ
and inﬂammation [71]. Another group of researchers has
recently described in a mouse model of infection with the
Colombian strain of T. cruzi (MHOM/CO/00/Colombian)
that the treatment with 15dPGJ2 reduces the inﬂammatory
inﬁltrate in the skeletal muscle at the site of infection
and decreases the number of lymphocytes and neutrophils
in the blood. These researchers also found that 15dPGJ2
also decreases the relative volume density of parasitic nests
in cardiac muscle [72]. Many works have described that
PPAR-α and PPAR-γ agonists play an important role in
regulating inﬂammation in diﬀerent models in vivo and in
vitro. Recently, the role of rosiglitazone, a PPAR-γ synthetic
agonist, in the modulation of the innate immune response
has been demonstrated in an experimental cerebral malaria
model (Reviewed in [70]). Also, it has been reported that
rosiglitazone together with antischistosomal drugs improves
the symptoms of liver ﬁbrosis induced by Schistosoma
japonicum in mice [70]. Besides, by linking metabolism and
immunity, Gallardo-Soler et al. proposed that PPAR activity
induces macrophage activation toward a more Th2 immune
phenotype in a model of Leishmania major infection. These
authors showed that PPAR-γ and PPAR-δ ligands promote
intracellular amastigote growth in infected macrophages,
and that this eﬀect is dependent on both PPAR expression
and arginase activity, suggesting that Arginase I is a key
marker of the alternative program triggered by PPAR in
macrophages [73].
Trypanosoma cruzi infection causes an intense inﬂam-
matory response in diverse tissues, including the heart.
The inﬂammatory reaction is critical for the control of
the parasites’ proliferation and evolution of Chagas disease.
15dPGJ2 can repress the inﬂammatory response in many
experimental models. However, the precise role of PPAR-γ
ligands in T. cruzi infection is poorly understood. Hovsepian
et al. (2011) have recently reported the ﬁrst evidence that
15dPGJ2 treatment increases the number of intracellular
parasites and inhibits the expression and activity of diﬀerent
inﬂammatory enzymes such as inducible nitric oxide syn-
thase (NOS2), matrix metalloproteinases 2 and 9 (MMP-2,
MMP-9), as well as proinﬂammatory cytokine (TNF-a and
IL-6) mRNA expression in neonatal mouse cardiomyocytes
after T. cruzi infection [12]( Figure 2). They also observed
that transfection of cardiomyocytes with small interfering
RNA (siRNA) induces silencing of PPAR-γ, impairing the
eﬀects of 15dPGJ2 on the modulation of proinﬂammatory
enzymes. In addition, they found that transfection restores
the ability of these cells to control the intracellular growth
of T. cruzi [12]. Like other nuclear receptors, PPARs are
phosphoproteins and their transcriptional activity is aﬀected
by crosstalk with kinases and phosphatases. In addition,
15dPGJ2 can act in a ligand-dependent or -independent
manner through mitogen-activated protein kinase (MAPK)
and nuclear factor-κB( N F - κB) [74]. Hovsepian et al.
(2011) demonstrated in T. cruzi-infected neonatal cardiac
cells that PPAR-γ-independent pathways are involved, sincePPAR Research 5
Cytosol
Nucleous
MEK 1/2
RXR
Corepressors
15dPGJ2
Inﬂammatory
genes
p50 p65
IKK
p50 p65
ERK1/2
Target genes PPRE
15dPGJ2
15dPGJ2
15dPGJ2
15dPGJ2
15dPGJ2
15dPGJ2 15dPGJ2
Trypomastigotes
Amastigotes
Transcription
factors
RXR
15dPGJ2
κ-B
PPAR-γ
PPAR-γ
3 5
Figure 2: Anti-inﬂammatory actions of 15dPGJ2 in T. cruzi-
infected cardiomyocytes. 15dPGJ2 can exert its eﬀects by binding
to PPAR-γ or through interaction with intracellular targets like
NF-κB-signaling pathway and Erk MAP kinase cascade. By PPAR-
γ-dependent mechanisms, the 15dPGJ2-PPAR-γ complex forms a
heterodimer with nuclear retinoid X receptor (RXR) to recognize
PPAR-response elements (PPREs) in the promoter region of the
target genes thereby stimulating their transcription. In the cytosol,
15dPGJ2 can also bind speciﬁc residues in IKK, p50, or p65
of the NF-κB-signaling pathway, or MEK1/2 and Erk1/2 in the
MAP kinase pathway leading to functional inactivation of inﬂam-
matory target genes. The consequent inhibition of inﬂammatory
factors/mediators by 15dPGJ2 promotes an increase in the number
of intracellular parasites.
15dPGJ2 also exerts its eﬀect through extracellular signal-
regulated kinases-mitogen-activated protein kinase (Erk-
MAPK) and NF-κB. The use of speciﬁc pharmacological in-
hibitors conﬁrmed these ﬁndings [12]( Figure 2). Our group
has recently found evidence about the role of 15dPGJ2 in
the regulation of inﬂammation parameters in a mouse-
experimental model of T. cruzi infection, conﬁrming all the
results assayed in neonatal cardiomyocytes (data not shown,
sent manuscript). In this manuscript, we report evidences
that 15dPGJ2 treatment inhibits TNFα and IL-6 mRNA
levels as well as the expression and activity of inﬂammatory
enzymes like NOS2 and MMP-2. We found that 15dPGJ2
participates in both parasitemia and amastigote nest regula-
tion in hearts of infected mice and that it does not modify
the mortality rate in acute infection. In the presence of
GW9662, a speciﬁc PPAR-γ antagonist, 15dPGJ2 partially
inhibited NOS2 expression and MMP-2 activity, denoting
the participation of some other signaling pathway. We also
found that NF-κB was activated by means of p65 nuclear
translocation in hearts of infected mice and inhibited after
15dPGJ2 treatment. These results highlight that both PPAR-
γ and NF-κB are implicated in the inhibitory eﬀects of
15dPGJ2 on the inﬂammatory response of the heart in an
acute model of T. cruzi infection (data not shown).
5.Perspectives
Todate,theaccurateroleofPPARligandsinT.cruziinfection
remains essentially unexplored. In this sense, some authors
argue that the expression of PPAR-γ decreases after T. cruzi
infection, while others argue that this expression increases.
However, in general, most research groups highlight the role
of PPARs in resolving inﬂammation and collaborating with
tissue repair in some cases. Therefore, we hope that PPARs
can potentially contribute to address a new pharmacological
approach to improve the host health.
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